Phase II Dose Titration Study in Patients With Neuropathic Pain
A Phase II, Multicentre, Pilot, Randomised, Double Blind Placebo Controlled Dose Titration Study to Evaluate the Safety, Maximum Tolerated Dose and Preliminary Evidence of Efficacy of Orally Administered Ralfinamide at Four Doses (80, 160, 240 and 320 mg/Day) in Patients With Neuropathic Pain
Sponsor: Newron Pharmaceuticals SPA
Listed as NCT00736151, this PHASE2 trial focuses on Neuropathic Pain and remains completed. Sponsored by Newron Pharmaceuticals SPA, it has been updated 8 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Apr 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
May 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Newron Pharmaceuticals SPA
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahmedabad, India , Bangalore, India , Bergamo, Italy , Bialobrzeska, Poland , Brno, Czechia , Brno-Bhunice, Czechia , Chennai, India , Chieti, Italy , Elblag, Poland , Ferrara, Italy and 32 more locations